Saibal Dey, PhD

Saibal Dey, PhD

Name: Saibal Dey, PhD

USU Department of Primary Appointment: 
Biochemistry
Title: 
Professor and Vice Chair
Faculty Rank: 
Full Professor
Location: 
Walter Reed National Military Medical Center, Bethesda, MD

Research Interests:
Membrane Transport
Multidrug Resistance

Email: 
saibal.dey@usuhs.edu
Office Phone: 
(301) 295-3449

Education

Ph.D., Biochemistry, Wayne State University School of Medicine, Detroit, Michigan (1994)
M. Sc., Zoology, Specialization: Cell Biology, University of Burdwan, West Bengal, India (1985)
B. Sc., Zoology, Minor: Botany and Chemistry, University of Burdwan, West Bengal, India (1983)


Representative publications, projects, and/or deployments

  • Vice Chair, Department of Biochemistry
  • Dean's Fellow, Uniformed Services University School of Medicine, (2018)
  • Module Director, Foundation in Medicine Module, Molecules to Military Medicine Curriculum, USU School of Medicine
  • "School of Medicine Dean's Teaching Award" in Basic Science, Uniformed Services University School of Medicine (2017)
  • “Hébert Impact Award” for outstanding contribution to the mission of the School, Uniformed Services University School of Medicine (2016)
  • “Hébert Impact Award” for outstanding contribution to the mission of the School, Uniformed Services University School of Medicine (2015)
  • “Recognition For Exemplary Support of the Molecules to Military Medicine Curriculum” Uniformed Services University School of Medicine Curriculum Reform (2011)
  • “Plank Holders of the Molecules to Military Medicine Curriculum”, for contribution to curriculum reform, Dean’s Office, Uniformed Services University School of Medicine (2011)
  • “Fellows Award for Research Excellence”, National Institutes of Health, Bethesda, Maryland. (1999)
  • “AACR-Genetics Institute Young Investigator Award”, in the annual meeting of The American Association For Cancer Research (1998)

Bibliography

  • Mandal, D., Moitra, K., Ghosh, D., Xia, D. and Dey, S. (2012) Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein. Biochemistry 51:2852-2866
  • Data, S., Mazumder, S., Ghosh, D., S., Dey, S., and Bhattacharya, S. (2009) Low concentration of arsenic induce caspase-3 mediated head kidney macrophage apoptosis with JNK-p38 activation in Claris batrachas. Toxicology and Applied Pharmacology 241:329-338
  • Fong, W. F., Wan, C. K., Zhu, G. Y., Chattopadhyay, A., Dey S., Zhao, Z., and Shen, X. L. (2007) Schisandrol A from Schisandra chnensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Medica, 73: 212-220.
  • Wan, C. K., Zhu, G. Y., Shen, X. L., Chattopadhyay, A., Dey, S., and Fong, W. F. (2006) Gomisin A alters substrate interaction and reverses P-glycoprotein mediated multidrug resistance in HepG2-DR cells. Biochemical Pharmacology, 72(7): 824-37
  • Maki, N., and Dey, S. (2006) Biochemical and pharmacological properties of an allosteric modulator site of human P-glycoprotein. Biochemical Pharmacology 72(2): 145-155
  • Maki, N., Moitra, K., Ghosh, P., and Dey, S. (2006) Allosteric modulation bypasses requirement for ATP hydrolysis in regenerating low-affinity transition state conformation of human P-glycoprotein. Journal of Biological Chemistry. 281(16): 10699-10777
  • Ghosh, P., Moitra, K., Maki, N., and Dey, S. (2006) Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates. Archives of Biochemistry and Biophysics. 450 (1): 100-112
  • Maki, N., Moitra, K., Silver, C., Ghosh, P., Chattopadhyay, A. K., and Dey, S. (2006) Modulator induced interference in functional cross talk between the substrate- and the ATP- sites of human P-glycoprotein. Biochemistry 45: 2739-2751
  • Maki, N., Hafkemeyer, P., and Dey, S. (2003). Allosteric modulation of human P-glycoprotein: Inhibition of transport by preventing substrate translocation and dissociation. Journal of Biological Chemistry. 278(20): 18132-18139.
  • Dey, S. (2002) Biricodar (Vertex Pharmaceuticals). Current Opinion in Investigational Drugs, Vol. 3(5): 818-823.